Stockreport

Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe

KIRIN HLDGS CO LTD S/ADR  (KNBWY) 
US:NASDAQ Investor Relations: kirinholdings.co.jp/english/ir
PDF Second- and third-line treatment for adults with mycosis fungoides or Sézary syndrome reimbursed by Croatia’s National Health Insurance Fund (NHIF), effective as of 15th [Read more]